Kiora Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
Kiora Pharmaceuticals, Inc. carries a market capitalization of 11.88M, placing it among publicly traded companies globally. Its enterprise value stands at -5.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.88M |
| Enterprise Value | -5.49M |
Share Statistics
Kiora Pharmaceuticals, Inc. currently has 3.99M shares outstanding.
| Shares Outstanding | 3.99M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.05 |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | -0.78 |
| P/OCF Ratio | -0.77 |
Financial Position
Kiora Pharmaceuticals, Inc. maintains a current ratio of 6.68, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.68 |
| Quick Ratio | 6.19 |
| Debt / Equity | 2.68 |
| Debt / EBITDA | -0.04 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -40.04 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -1.41M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Kiora Pharmaceuticals, Inc.'s stock has declined approximately -31.28205% over the past 52 weeks. The 50-day moving average sits at 2.41, while the 200-day moving average is 2.34.
| Beta (5Y) | N/A |
| 52-Week Price Change | -31.28205% |
| 50-Day Moving Average | 2.41 |
| 200-Day Moving Average | 2.34 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.87M, while operating income came in at -9.91M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -9.91M |
| Pretax Income | -12.47M |
| Net Income | -11.06M |
| EBITDA | -9.87M |
| EBIT | -9.91M |
| Earnings Per Share (EPS) | -2.65 |
Balance Sheet
Kiora Pharmaceuticals, Inc. holds 13.87M in cash and equivalents against 373,586.00 in total debt, resulting in a net debt position of -10.96M. Total book value stands at -156.36M, with working capital of 15.88M providing operational flexibility.
| Cash & Cash Equivalents | 13.87M |
| Total Debt | 373,586.00 |
| Net Debt | -10.96M |
| Equity (Book Value) | -156.36M |
| Book Value Per Share | -37.67 |
| Working Capital | 15.88M |
Cash Flow
Kiora Pharmaceuticals, Inc. produced -10.42M in operating cash flow over the past twelve months. After subtracting -115,807.00 in capital expenditures, free cash flow totaled -10.53M - equivalent to -2.54 per share.
| Operating Cash Flow | -10.42M |
| Capital Expenditures | -115,807.00 |
| Free Cash Flow | -10.53M |
| FCF Per Share | -2.54 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -3.31 |
| FCF Yield | -127.85 |
Stock Splits
Kiora Pharmaceuticals, Inc.'s most recent stock split took place on June 11, 2024 with a 9:1 split ratio.
| Last Split Date | 6/11/2024 |
| Split Ratio | 9:1 |
Scores
Kiora Pharmaceuticals, Inc. posts an Altman Z-Score of -11.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -11.49 |